Chondroitin Sulfate CS b-Bioactive Delays the Progression of Knee Osteoarthritis, Study Finds

beadbb9b-265e-4f43-972f-34f9381b5b8carticleimage.jpg

28 Jun 2017 --- Bioiberica’s Chondroitin sulfate CS b-Bioactive delays osteoarthritis progression and is as effective as the anti-inflammatory drug celecoxib at improving the disease’s symptoms. These are the main conclusions of a clinical essay presented by Professor Jean Pierre Pelletier at the Annual European Congress of Rheumatology, held in Madrid. Conducted by Bioiberica, the MOSAIC clinical essay (a 24-month study on structural changes in knee osteoarthritis assessed by MRI with Chondroitin sulfate) is a multicenter, randomized, double-blind, controlled and comparative study, carried out in five medical centers in Quebec (Canada). 

A total of 194 patients suffering from knee osteoarthritis with inflammation (synovitis) and moderate pain participated in the study to assess the effects of chondroitin sulfate (1.200 mg/day) and celecoxib (200 mg day) over the loss of cartilage volume in knee osteoarthritis after 24 months. 

The participants underwent three Quantitative Magnetic Resonance scans: one at the beginning of the study, the second one after one year and a third one at the end of the study. The results revealed that the progression of knee osteoarthritis is slower in patients who received chondroitin sulfate CS b-Bioactive. This group experienced a statistically significant lower loss of cartilage volume as soon as after the first year of treatment, in comparison with those patients who received the anti-inflammatory drug.

Patients treated with chondroitin sulfate had a decrease in synovitis which was associated with a statistically significant decrease in cartilage loss. In addition to that, a post hoc analysis of this clinical trial concludes that chondroitin sulfate also has a protective effect by reducing the long-term progression of knee OA structural changes caused by a decrease in the loss of subchondral bone curvature. 

“This data proves that chondroitin sulfate may delay the advance of osteoarthritis in the long term, and identifies a possible new mode of action of chondroitin sulfate,” Professor Pelletier said. 

The MOSAIC study also evaluated the effects of both products on the disease’s symptoms. Among others, the study evaluated their effects on pain, function, stiffness, joint swelling and effusion; concluding that both treatments were equally efficient across the entire study, reaching a clinically relevant symptom improvement of around 50 percent.

“The study confirms that both products are effective for the treatment of osteoarthritis symptoms, although only chondroitin sulfate has the additional advantage of exerting a joint protection effect,” Professor Pelletier concludes.

To contact our editorial team please email us at editorial@cnsmedia.com

Bioiberica S.A.U.

Collapse

Bioiberica is a biotechnology company specialized in the research, development, production and distribution of biomolecules such as Chondroitin Sulfate, Glucosamine and Hyaluronic Acid for the nutraceutical, pharmaceutical and food industries.

Since 1975, Bioiberica has consolidated its position as an international leader in joint health, thanks to a constant dedication to science and technology.  

Vertically integrated, from the active ingredient to the finished product, Bioiberica places all its medical, scientific and marketing knowledge at the client’s disposal to achieve a leading and innovative line of joint care products.

Bioiberica offers a wide range of innovative and scientifically based branded ingredients for mobility and joint health.

MOBILEE® the First Health Ingredient for Mobility



Mobilee® is an innovative branded ingredient for joint mobility and muscular strength.
It is a patented natural ingredient with a unique composition rich in hyaluronic acid, collagen and other polysaccharides.

The efficacy of Mobilee® in improving joint mobility and muscle strength has been demonstrated in four double blind placebo-controlled randomized clinical trials.

Due to its excellent safety profile, Mobilee® has been approved as Novel Food by the EFSA and has the GRAS status in the USA.

Thanks to its low dose Mobilee® is easy to formulate and can be easily combined with other ingredients.

Mobilee® has been researched and developed by Bioiberica, the Joint Health expert.



b-2Cool® is a natural ingredient supplying native type II collagen.

Thanks to its native form, orally taken b-2Cool works through an immune-mediated mechanism of action called ORAL TOLERANCE, that modulates the immune response against endogenous type II collagen.

It allows b-2Cool® to reduce cartilage degradation and joint inflammation, thus improving joint pain and function.

Tendofit® is a proprietary complex with a unique formula especially designed for tendon health and recovery. 

More that 6 scientific studies support its effectiveness.

Clinical benefits of Tendofit®

Tendon structure recovery

Pain relief

Anti-inflammatory effect

Fast return activity

CS b-Bioactive® is #1 researched chondroitin. Its efficacy has been tested in +20 clinical studies and +5,000 patients.

CS b-Bioactive® has demonstrated to be better absorbed and have higher biological effects compared to other chondroitins.

It is manufactured to the highest pharmaceutical standards, being the reference standard of EP & USP.


Acti-Joint® is a proprietary formula that has demonstrated a superior effect compared to the standard combination Glucosamine 1,500 mg. - Chondroitin 1,200 mg.

Acti-Joint® composition:

b-Glu (Bioiberica’s glucosamine) 1,500 mg

CS b-Bioactive® (Bioiberica’s chondroitin sulfate) 200 mg

Mobilee® (Natural ingredient rich in hyaluronic acid, polysaccharides and collagen) 20 mg

Palbio® is a cartilage complex containing chondroitin sulfate, hydrolyzed collagen and tricalcium phosphate, specially formulated to supply the main components of the joint in directly related nutritional values.

The unique, carefully studied composition of Palbio nourishes the joint and improves its metabolism.

Related Articles

Nutrition & Health News

Labeling debate: Health labels may deter people from buying sugary drinks

25 May 2018 --- Young adults are less likely to buy sugar-sweetened beverages that include health labels, particularly those with graphic warnings about how added sugar can lead to tooth decay, obesity and Type 2 diabetes, according to research presented at this year's European Congress on Obesity (ECO) in Vienna this week. 

Nutrition & Health News

Weekly Digest: Arla expands fiber yogurt range, probiotics may reduce hay fever symptoms

25 May 2018 --- This week in nutrition news, Arla revealed a new addition to its fiber yogurt range, hoping to boost the UK's daily fiber intake. In research news, probiotic formulations were found to have positive effects on hay fever symptoms, while following a diet high in antioxidants may protect people from the adverse effects of pollution. Furthermore, researchers have made steps in understanding the link between a mothers nutrition during pregnancy and the child's growth, and a study undercovered that consumers are more likely to order unhealthy options when dining out amid louder, ambient music.

Nutrition & Health News

Avoid the snacks? To manage weight, timing of protein supplements matters

25 May 2018 --- Protein supplementation is finding its way into an ever-increasing range of formats, with on-the-go snacks and “bite-size” in particular seeing tremendous growth. However, new research by nutrition experts at Purdue University has shown that people looking to manage their weight with strength-training and protein supplements should consume their supplementation during a meal. 

Nutrition & Health News

DuPont's probiotic reach expands with Brazilian recognition of health claim

25 May 2018 --- DuPont Nutrition & Health Science has earned approval from the Brazilian Health Regulatory Agency (ANVISA) for its Bifidobacterium lactis HN019 probiotic strain. The regulatory green light marks the recognition of the science behind the strain and allows an on-pack health claim. Customers in Brazil can now bring new probiotic products and dietary supplements faster to market using the first DuPont probiotic to qualify for an approved health claim on the local market.

Nutrition & Health News

Athletic endurance improved with Beneo's low glycemic carb, study finds

24 May 2018 --- Athletes who consumed a drink containing the functional carbohydrate, Palatinose, before exercise exhibited improved cycling performance, a study at the University of Freiburg has found. This was in comparison with participants who were given maltodextrin, a high glycemic carbohydrate, before exercising. The study's findings could hold potential for the use of Palatinose as a sports nutrition ingredient.

More Articles
URL : http://www.nutritioninsight.com:80/news/chondroitin-sulfate-cs-b-bioactive-delays-the-progression-of-knee-osteoarthritis-study-finds.html